According to a statement issued by the drug maker, #39;Tosymra#39; (previously known as DFN-02), is the latest product to join the Dr Reddy#39;s US subsidiary Promius Pharma#39;s acute migraine treatment portfolio.
Subscribe to:
Post Comments (Atom)
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Thirteen tier 2 and 3 cities register higher traffic in December than pre-COVID-19 levels.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment